The table below shows Cellectar Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$23.12M
-$47.58M
-$32.38M
-$25.22M
-$22.57M
-$13.93M
Capital expenditure
$5.88K
$104.19K
$864.04K
$225.97K
$141.36K
$62.35K
Investing cash flow
-$5.88K
-$104.19K
-$864.04K
-$225.97K
-$141.36K
-$62.35K
Dividends paid
-
-
-
-
CLRB operating cash flow (10-K history)
Cellectar Biosciences, Inc. reported operating cash flow of -$23.12M for fiscal year 2025. That is up 51.4% from -$47.58M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$8.28M (FY 2016) to -$23.12M. Figures come from the company's audited annual reports as filed with the SEC.